Cargando…

Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer

BACKGROUND: The Glycine N-acyltransferase (GLYAT) gene encodes a protein that catalyzes the transfer of acyl groups from acyl CoA to glycine, resulting in acyl glycine and coenzyme A. Aberrant GLYAT expression is associated with several malignant tumors, but its clinical importance in human breast c...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Xin, Wu, Lina, Jiang, Min, Zhang, Zhenyong, Wu, Rong, Miao, Jianing, Liu, Caigang, Gao, Song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100313/
https://www.ncbi.nlm.nih.gov/pubmed/33968740
http://dx.doi.org/10.3389/fonc.2021.641399
_version_ 1783688759632461824
author Tian, Xin
Wu, Lina
Jiang, Min
Zhang, Zhenyong
Wu, Rong
Miao, Jianing
Liu, Caigang
Gao, Song
author_facet Tian, Xin
Wu, Lina
Jiang, Min
Zhang, Zhenyong
Wu, Rong
Miao, Jianing
Liu, Caigang
Gao, Song
author_sort Tian, Xin
collection PubMed
description BACKGROUND: The Glycine N-acyltransferase (GLYAT) gene encodes a protein that catalyzes the transfer of acyl groups from acyl CoA to glycine, resulting in acyl glycine and coenzyme A. Aberrant GLYAT expression is associated with several malignant tumors, but its clinical importance in human breast cancer (BC), has yet to be fully addressed. This study aims to evaluate the clinical function of GLYAT in BC patients. METHODS: GLYAT expression was determined by immune blot and immunohistochemistry in three BC cell lines and primary cancer tissues. The MDA-MB 231 cell line was used for GLYAT gene knockdown experiments while the MCF7 cell line for overexpression experiments. Colony formation experiments, soft agar experiments, and transwell assays were utilized for further inspection of cell proliferation and migration capabilities. Immunofluorescence and western blot were used to detect markers of the epithelial-mesenchymal transition (EMT) and changes in the PI3K/AKT/Snail pathway. The role of GLYAT in tumor growth and metastasis was also assessed in nude mice in vivo. Also, a correlation analysis was performed between clinicopathological features and GLYAT expression in BC patients. RESULTS: GLYAT was decreased in human BC tissues and cell lines. Functional analysis showed that knockdown of GLYAT augmented BC cell proliferation in vitro and in vivo. However, this phenomenon was reversed when GLYAT was overexpressed in the transfected cells. Moreover, downregulation of GLYAT promoted the migratory properties of BC cells, likely through the activation of PI3K/AKT/Snail signaling, which subsequently induced the EMT. IHC analysis indicated that GLYAT was decreased in human BC tissues and lower GLYAT expression was correlated with histological grade, tumor TNM stage, Ki-67 status, and poorer survival in BC patients. Furthermore, lower GLYAT expression seemed as an independent risk factor related to poor prognosis in BC patients based on Cox regression analyses. CONCLUSION: Our findings demonstrate that downregulation of GLYAT expression in human breast cancer is correlated with EMT via the PI3K/AKT/Snail pathway and is also associated with histological grade, tumor TNM stage, Ki-67 status, and poor survival in breast cancer patients.
format Online
Article
Text
id pubmed-8100313
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81003132021-05-07 Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer Tian, Xin Wu, Lina Jiang, Min Zhang, Zhenyong Wu, Rong Miao, Jianing Liu, Caigang Gao, Song Front Oncol Oncology BACKGROUND: The Glycine N-acyltransferase (GLYAT) gene encodes a protein that catalyzes the transfer of acyl groups from acyl CoA to glycine, resulting in acyl glycine and coenzyme A. Aberrant GLYAT expression is associated with several malignant tumors, but its clinical importance in human breast cancer (BC), has yet to be fully addressed. This study aims to evaluate the clinical function of GLYAT in BC patients. METHODS: GLYAT expression was determined by immune blot and immunohistochemistry in three BC cell lines and primary cancer tissues. The MDA-MB 231 cell line was used for GLYAT gene knockdown experiments while the MCF7 cell line for overexpression experiments. Colony formation experiments, soft agar experiments, and transwell assays were utilized for further inspection of cell proliferation and migration capabilities. Immunofluorescence and western blot were used to detect markers of the epithelial-mesenchymal transition (EMT) and changes in the PI3K/AKT/Snail pathway. The role of GLYAT in tumor growth and metastasis was also assessed in nude mice in vivo. Also, a correlation analysis was performed between clinicopathological features and GLYAT expression in BC patients. RESULTS: GLYAT was decreased in human BC tissues and cell lines. Functional analysis showed that knockdown of GLYAT augmented BC cell proliferation in vitro and in vivo. However, this phenomenon was reversed when GLYAT was overexpressed in the transfected cells. Moreover, downregulation of GLYAT promoted the migratory properties of BC cells, likely through the activation of PI3K/AKT/Snail signaling, which subsequently induced the EMT. IHC analysis indicated that GLYAT was decreased in human BC tissues and lower GLYAT expression was correlated with histological grade, tumor TNM stage, Ki-67 status, and poorer survival in BC patients. Furthermore, lower GLYAT expression seemed as an independent risk factor related to poor prognosis in BC patients based on Cox regression analyses. CONCLUSION: Our findings demonstrate that downregulation of GLYAT expression in human breast cancer is correlated with EMT via the PI3K/AKT/Snail pathway and is also associated with histological grade, tumor TNM stage, Ki-67 status, and poor survival in breast cancer patients. Frontiers Media S.A. 2021-04-22 /pmc/articles/PMC8100313/ /pubmed/33968740 http://dx.doi.org/10.3389/fonc.2021.641399 Text en Copyright © 2021 Tian, Wu, Jiang, Zhang, Wu, Miao, Liu and Gao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Tian, Xin
Wu, Lina
Jiang, Min
Zhang, Zhenyong
Wu, Rong
Miao, Jianing
Liu, Caigang
Gao, Song
Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer
title Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer
title_full Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer
title_fullStr Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer
title_full_unstemmed Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer
title_short Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer
title_sort downregulation of glyat facilitates tumor growth and metastasis and poor clinical outcomes through the pi3k/akt/snail pathway in human breast cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100313/
https://www.ncbi.nlm.nih.gov/pubmed/33968740
http://dx.doi.org/10.3389/fonc.2021.641399
work_keys_str_mv AT tianxin downregulationofglyatfacilitatestumorgrowthandmetastasisandpoorclinicaloutcomesthroughthepi3kaktsnailpathwayinhumanbreastcancer
AT wulina downregulationofglyatfacilitatestumorgrowthandmetastasisandpoorclinicaloutcomesthroughthepi3kaktsnailpathwayinhumanbreastcancer
AT jiangmin downregulationofglyatfacilitatestumorgrowthandmetastasisandpoorclinicaloutcomesthroughthepi3kaktsnailpathwayinhumanbreastcancer
AT zhangzhenyong downregulationofglyatfacilitatestumorgrowthandmetastasisandpoorclinicaloutcomesthroughthepi3kaktsnailpathwayinhumanbreastcancer
AT wurong downregulationofglyatfacilitatestumorgrowthandmetastasisandpoorclinicaloutcomesthroughthepi3kaktsnailpathwayinhumanbreastcancer
AT miaojianing downregulationofglyatfacilitatestumorgrowthandmetastasisandpoorclinicaloutcomesthroughthepi3kaktsnailpathwayinhumanbreastcancer
AT liucaigang downregulationofglyatfacilitatestumorgrowthandmetastasisandpoorclinicaloutcomesthroughthepi3kaktsnailpathwayinhumanbreastcancer
AT gaosong downregulationofglyatfacilitatestumorgrowthandmetastasisandpoorclinicaloutcomesthroughthepi3kaktsnailpathwayinhumanbreastcancer